Unicycive Therapeutics (NASDAQ:UNCY) Earns Buy Rating from HC Wainwright

Unicycive Therapeutics (NASDAQ:UNCY)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $4.00 price objective on the stock. HC Wainwright’s price objective would indicate a potential upside of 440.54% from the company’s previous close.

Separately, Benchmark reissued a “speculative buy” rating and issued a $3.00 price target on shares of Unicycive Therapeutics in a research note on Friday, November 22nd. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $5.50.

Unicycive Therapeutics Trading Down 4.9 %

Shares of NASDAQ:UNCY opened at $0.74 on Wednesday. The business has a 50-day moving average price of $0.65 and a 200 day moving average price of $0.49. Unicycive Therapeutics has a 12-month low of $0.20 and a 12-month high of $1.82. The company has a market capitalization of $76.81 million, a price-to-earnings ratio of -0.76 and a beta of 2.30.

Hedge Funds Weigh In On Unicycive Therapeutics

Several institutional investors have recently bought and sold shares of UNCY. Great Point Partners LLC acquired a new stake in shares of Unicycive Therapeutics during the third quarter worth about $3,491,000. Walleye Capital LLC acquired a new stake in Unicycive Therapeutics during the 3rd quarter worth approximately $2,040,000. Acuta Capital Partners LLC acquired a new stake in Unicycive Therapeutics during the 3rd quarter worth approximately $807,000. Bleakley Financial Group LLC purchased a new position in Unicycive Therapeutics in the 3rd quarter valued at approximately $33,000. Finally, XTX Topco Ltd acquired a new position in shares of Unicycive Therapeutics in the third quarter worth $29,000. 40.42% of the stock is owned by institutional investors and hedge funds.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.